FDA clears first generic pergolide tablet for horses with PPID

A new FDA-approved generic option has arrived for one of equine practice’s most familiar endocrine diseases. Zygolide, a pergolide tablet from Dechra Veterinary Products, was approved for control of clinical signs associated with pituitary pars intermedia dysfunction, or PPID, in horses, making it the first generic pergolide tablet approved for this indication in the U.S. The FDA announced the approval on January 9, 2026, following the product’s December 19, 2025 approval date in the agency’s filing records. (fda.gov)

That matters because pergolide has long been the standard medical therapy for equine Cushing’s disease, particularly in older horses managing chronic endocrine dysfunction and laminitis risk. Until now, the reference listed product in the U.S. market was Prascend. FDA records identify Prascend as the reference listed new animal drug for Zygolide’s abbreviated approval, meaning the generic cleared the regulatory pathway by demonstrating bioequivalence rather than re-running full effectiveness studies from scratch. (animaldrugsatfda.fda.gov)

The label details are familiar to veterinarians already treating PPID, but the commercial framing is different. Zygolide is a 1 mg oral pergolide tablet, with a labeled starting dose of 2 mcg/kg once daily and dose adjustments up to 4 mcg/kg daily. The product insert says the tablets are half-scored and should be dosed to the nearest one-half tablet. It also includes handling precautions: tablets should not be crushed because of the potential for increased human exposure, and pregnant or lactating women should wear gloves when administering the product. Promotional content carried by The Horse and retail listings have stressed peppermint flavoring and dosing convenience, positioning the product around day-to-day compliance as much as pharmacology. (dechra-us.com)

The FDA’s freedom of information summary offers the clearest regulatory snapshot. It states that Zygolide is the first generic pergolide tablet for horses and that approval was supported by an in vivo blood-level study showing bioequivalence to 1 mg Prascend tablets, with no serious adverse events reported during that study. The same product materials cite the historical effectiveness data underlying pergolide’s use in PPID: in an open-label field study of 113 evaluable horses, 76.1% were classified as treatment successes by Day 180 based on endocrine testing and clinical assessment, and 41.6% required a dose increase at Day 90. (animaldrugsatfda.fda.gov)

Industry reaction so far has been more practical than dramatic. Dechra and trade-facing materials are emphasizing that this is a first-to-market generic and that it is designed specifically for horses. Independent equine outlets and clinic notices have focused on the same likely selling points: a new FDA-approved alternative, easier dose adjustment, and the potential for cost relief in a disease that often requires lifelong therapy. I didn’t find substantive quoted reaction yet from major veterinary associations or equine internists specifically addressing Zygolide by name, which suggests the professional conversation is still in its early commercial phase. (equinefacilitydesign.com)

Why it matters: For veterinary professionals, this launch is less about a new mechanism than about access, adherence, and case management. PPID treatment often becomes a long-term balancing act involving endocrine monitoring, laminitis prevention, appetite issues, and gradual dose titration. Equine Endocrinology Group materials continue to position pergolide as the recommended medical treatment for PPID, with follow-up based on both clinical response and endocrine testing. In that context, a generic product could reduce cost pressure for pet parents and barns, while features like flavoring and scored tablets may help in horses that resist daily medication. At the same time, veterinarians will still need to counsel clients on safe handling, monitor for inappetence and dose intolerance, and keep expectations grounded: a generic may improve access, but it doesn’t simplify the disease itself. (equineendocrinologygroup.org)

There’s also a regulatory and prescribing angle. Because Zygolide is FDA-approved and prescription-only, it gives veterinarians another labeled option in a category where compounded pergolide has historically been part of the conversation, especially in difficult dosing situations. The existence of an approved generic may influence how clinicians weigh approved products versus compounded alternatives, particularly when consistency, handling, and pharmacy access are part of the discussion. That’s an inference based on the new approval and longstanding PPID treatment patterns, rather than a formal policy statement from regulators. (fda.gov)

What to watch: The next signals will be commercial, not scientific: pharmacy uptake, real-world pricing, whether Dechra expands distribution through major equine channels, and whether veterinarians see measurable improvement in refill persistence or dose compliance during 2026. If those early indicators are positive, Zygolide could become a meaningful operational change in PPID management, even if the underlying medicine is well established. (equinefacilitydesign.com)